October 2026: Bombay HC Upholds Ban on Duty-Free Nicotine Pouches, Rules Out Immunity from Domestic Laws
In a ruling clarifying the reach of Indian regulatory oversight, the Bombay High Court dismissed two writ petitions filed by duty-free operators at Chhatrapati Shivaji Maharaj International Airport (Mumbai). The decision upholds a ban on the sale of imported, tobacco-free nicotine pouches at the airport, affirming that duty-free outlets inside customs zones remain bound by domestic public health regulations.
The litigation arose after drug control authorities moved to stop duty-free retailers from stocking and selling imported nicotine pouches. Authorities classified the products as drugs under the Drugs and Cosmetics Act, 1940, which requires specific compliance and licensing for import, storage, and distribution. Challenging the ban, the petitioners argued that duty-free shops operating beyond the customs frontier cater primarily to outbound international passengers. They contended that goods sold within these areas should enjoy regulatory immunity from domestic statutory frameworks because the items do not technically enter the local domestic market.
A bench of the Bombay High Court rejected the petitioners’ jurisdictional argument, establishing two pivotal conclusions:
First, regarding territorial applicability, the High Court clarified that being located within a designated customs area or beyond customs barriers does not strip a commercial entity of its obligation to comply with Indian law. Duty-free shops physically sit within Indian sovereign territory, making their commercial transactions subject to domestic statutory regulations, including public health mandates.
Second, regarding classification, the court sustained the regulatory classification of nicotine pouches as drugs under the Drugs and Cosmetics Act, 1940. Consequently, selling or distributing these products requires mandatory licensing and regulatory clearance from domestic health authorities.
The dismissal of the writ petitions reinforces the legal authority of Indian health officials over retail practices within international transport hubs. By establishing that duty-free areas are not extraterritorial safe harbors, the judgment sets a strong precedent: fiscal tax concessions provided to international travelers do not equate to regulatory exemptions from public safety and health laws. As a result, duty-free operators nationwide must ensure that all new nicotine products meet strict licensing requirements set by Indian regulatory authorities before offering them to travelers.
September 2026: India Orders Nationwide Crackdown on Nicotine Pouches Citing Severe Health Risks
The Indian government has ordered state authorities to initiate a strict crackdown on the sale and distribution of nicotine pouches, warning that the globally popular, tobacco-free alternatives pose significant public health and addiction risks. In a directive issued by the health ministry to all states, officials emphasized that these products remain illegal and unapproved under domestic laws. Despite lacking regulatory approval, products from prominent international brands such as Zyn and White Fox have increasingly found their way into the country through smuggling and unauthorized online and offline channels.
The government’s hard-line stance follows a federal study published in June, which flagged nicotine pouches as a “largely unregulated public health concern”. Consumption of the pouches has notably ticked upward among young adults aged 18 to 40, while health authorities have expressed acute anxiety over growing nicotine exposure and addiction among children. Under the health ministry’s latest instructions, states have been urged to utilize provisions of India’s drug laws to conduct searches, seize unapproved stock, and prosecute vendors engaged in the illicit trade.
The crackdown coincides with broader institutional resistance against alternative nicotine products in India. While the country maintains a nationwide ban on e-cigarettes and heated tobacco products, it permits specific therapeutic smoking-cessation aids like nicotine patches and chewing gums. However, India’s Drugs Technical Advisory Board noted in recent meeting minutes that nicotine pouches are addictive, present independent health risks, and have not been scientifically established as effective aids to quit smoking. Consequently, the federal drug panel has recommended that no new nicotine formulations be granted approval moving forward.
Regulatory scrutiny has also spilled over into high-profile commercial disputes. An ongoing legal battle has targeted duty-free shops at Mumbai’s international airport – operated by billionaire Gautam Adani’s conglomerate – after an investigation revealed they had been selling nicotine pouches in contravention of domestic statutes. While corporate representatives have defended their operations, local courts have maintained that duty-free outlets are not immune to national health and safety regulations.
September 2026: India’s Tobacco Control Authority Recommends Rejection of Nicotine Pouch Manufacturing Licenses
India’s National Tobacco Control Programme (NTCP) has recommended the rejection of applications for manufacturing and import licenses for oral nicotine pouches, reinforcing New Delhi’s firm policy stance against emerging recreational nicotine products. The recommendation by the health division aims to prevent tobacco-free nicotine pouches from establishing a legal commercial presence in the domestic market.
Under India’s current regulatory framework, nicotine products are governed strictly by therapeutic intent. Nicotine replacement therapies, such as specific gums and patches, are regulated under the Drugs and Cosmetics Act, 1940, as approved smoking-cessation aids. In contrast, non-therapeutic or recreational nicotine pouches have no established legal consumer pathway in India. Because oral pouches contain no electronic heating components, they fall outside the scope of the Prohibition of Electronic Cigarettes Act, 2019, while also sitting outside the traditional tobacco product definitions outlined in the Cigarettes and Other Tobacco Products Act (COTPA), 2003.
Despite the lack of explicit statutory approvals, foreign and domestic manufacturers have attempted to introduce oral nicotine pouches into the country, prompting increased scrutiny from regulators. Recent investigations and studies by the Indian Council of Medical Research (ICMR) revealed that unapproved pouches have circulated through online channels, specialty retailers, and airport duty-free shops. In response, health authorities and the Central Drugs Standard Control Organization (CDSCO) have classified recreational oral pouches as unapproved drug products, warning of the public health risks posed by unregulated psychoactive nicotine consumption.
The NTCP’s recommendation to deny manufacturing and import clearances aligns with broader government directives to close regulatory loopholes. By advising licensing bodies and the Directorate General of Foreign Trade (DGFT) to withhold approvals, public health officials aim to prevent manufacturers from using cessation aid frameworks to commercialize consumer nicotine products, cementing India’s strict stance against non-therapeutic nicotine distribution.
July 2026: Customs Joins Health Ministry in Fight Against Adani Over Illegal Airport Nicotine Pouch Sales
In a major escalation over the regulation of alternative tobacco products, India’s customs authorities have aligned with the Union Health Ministry in a high-stakes legal battle against the Adani Group over the sale of nicotine pouches at airport duty-free shops. The dispute, currently playing out in the Bombay High Court, centers on whether duty-free zones at international airports are exempt from India’s stringent domestic drug and public health regulations.
The controversy began following an investigation by India’s drug regulatory department, prompted by complaints from public health advocacy groups like Mothers Against Vaping. During an inspection at Mumbai’s Chhatrapati Shivaji Maharaj International Airport – operated by a joint venture led by billionaire Adani’s business group – officials discovered that duty-free shops in the international departure zone were illegally stocking and selling imported nicotine pouches. Among the seized items were Philip Morris International (PMI)’s highly popular ZYN brand. Under Indian law, nicotine pouches are classified as “drugs.” Because they have not undergone the country’s mandatory registration and approval processes, their import and sale remain strictly illegal.
In response to the regulatory crackdown, Adani’s retail unit, Mumbai Travel Retail, sought judicial review. The company argued that international duty-free shops operate “beyond the customs frontiers of India” and should therefore be exempt from domestic regulations. They further contended that nicotine pouches are a “recent innovation” not anticipated by older tobacco laws and that because the products are sold in sealed bags to departing international passengers, they are not intended for consumption on Indian soil.
Both the Central Drugs Standard Control Organisation (CDSCO) and the Indian Customs authority have strongly rejected Adani’s arguments in court. In its latest filings, the customs department clarified that “outside customs frontiers” is a concept reserved strictly for taxation and duty benefits, emphasizing that tax exemptions do not grant duty-free shops immunity from national regulatory and health controls. Government lawyers dismissed Adani’s argument regarding departing passengers, pointing out that once travelers take possession of the pouches, they can freely consume them. Furthermore, the government firmly asserted that the airport is physically on Indian soil and subject to domestic law.
The CDSCO labeled the airport sales a “substantive violation” of drug laws, warning that allowing the sale of unlicensed, unapproved nicotine delivery systems poses a “serious public health risk” and exposes consumers to products of unverified quality and safety. The government also cited India’s landmark 2019 ban on e-cigarettes and vapes, arguing that allowing duty-free sales would represent a “judicial circumvention” of established legislative policies to curb nicotine addiction.
The aggressive stance taken by the Indian government against nicotine pouches is deeply rooted in the country’s unique public health landscape. India is the world’s largest smokeless tobacco market, with a staggering number of users that eclipses the rest of the world combined. Historically, traditional smokeless products – such as khaini, gutkha, and pan masala – have been highly prevalent across the country, used by over 200 million Indians. This widespread consumption of smokeless tobacco has created a massive public health crisis, leaving India with the highest burden of oral cancer globally.
Because of this existing epidemic, public health officials are highly sensitive to the introduction of modern smokeless alternatives like ZYN. The Health Ministry fears that if nicotine pouches – often marketed as modern, clean, or discreet – are permitted to bypass regulatory frameworks through duty-free loopholes, they could trigger a new wave of nicotine addiction, particularly among younger demographics.
As the Bombay High Court prepares for further hearings, the outcome of the case is expected to set a critical precedent. A victory for the government would solidify India’s absolute authority to regulate public health hazards within its borders, effectively slamming the door on the sale of unapproved nicotine pouches at all international transit hubs in the country.
May 2026: Godfrey Phillips India Enters 3-Year Distribution Agreement for NRT Products in Strategic Move Into Smokeless Category
Godfrey Phillips India has entered a three-year distribution agreement with Aspeya India to market and distribute nicotine replacement therapy (NRT) products across India, using its established retail and distribution network. The partnership allows Godfrey Phillips to expand beyond traditional tobacco into the regulated health and wellness segment.
The structure of the deal carries broader industry significance. Philip Morris International (PMI) is the foreign promoter shareholder of Godfrey Phillips India, while Aspeya is a fully owned PMI subsidiary focused consumer health and oral delivery technologies. The agreement comes against a restrictive regulatory backdrop in India, where nicotine pouches are currently banned. This limits access to modern oral nicotine formats and has pushed companies toward alternative, compliant pathways such as medically positioned NRT products. PMI’s structure in this deal suggests an effort to maintain exposure to India’s large smokeless nicotine demand through regulated channels rather than consumer pouch formats.
The arrangement strengthens PMI’s indirect positioning in India’s nicotine ecosystem by combining Godfrey Phillips’ domestic distribution reach with Aspeya’s product capabilities, while operating within the existing regulatory constraints.
